9月22日，Ultragenyx Pharmaceutical盘中上涨9.39%，报16.025美元/股，成交额6472.9万美元，延续此前FDA获批后的上行动能。
消息面上，FDA于上周批准公司旗下基因疗法Fayuvi，用于治疗A型Sanfilippo综合征（MPS IIIA）儿童患者，系该适应症首个获批疗法。Fayuvi通过一次性静脉输注递送功能性基因，临床试验显示2至5岁患儿认知能力获得维持或改善。该药每位患者批发采购成本定为395万美元，为公司第六项FDA批准及第二款获批基因疗法。此前公司因Angelman综合征药物三期试验失败股价一度重挫逾45%，Fayuvi的获批在一定程度上修复了市场对公司管线价值的信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.